Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor
Clinicaltrials.gov identifier:
NCT06065059
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor
Study Contact Information:
Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor
About the Study
This study is no longer recruiting patients.
The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with (a .) The study is for patients who have advanced breast, ovarian, pancreatic, and cancer and a or mutation or have an positive tumor.
This study is no longer recruiting patients.
This study is no longer recruiting patients.